和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

休市中 12-06 16:08:03

4.860

+0.110

+2.32%

最高4.910	最低4.700	成交量196.90万
今开4.750	昨收4.750	日振幅4.42%
总市值33.05亿	流通市值33.05亿	总股本6.80亿
成交额953.87万	换手率0.29%	流通股本6.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":4.86,"timestamp":1733472483014,"preClose":4.75,"halted":0,"volume":1969000,"delay":0,"floatShares":680000000,"shares":680000000,"eps":-0.7123305,"marketStatus":"休市中","marketStatusCode":7,"change":0.11,"latestTime":"12-06 16:08:03","open":4.75,"high":4.91,"low":4.7,"amount":9538660,"amplitude":0.044211,"askPrice":4.86,"askSize":1000,"bidPrice":4.82,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":-0.026908191039295464,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1733707800000},"adr":0,"listingDate":1634054400000,"adjPreClose":4.75,"openAndCloseTimeList":[[1733448600000,1733457600000],[1733461200000,1733472000000]],"volumeRatio":0.46798497883567086,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2489758284","title":"和誉：ABSK043单药具有良好的安全性和抗肿瘤活性","url":"https://stock-news.laohu8.com/highlight/detail?id=2489758284","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489758284?lang=zh_cn&edition=full","pubTime":"2024-12-06 13:34","pubTimestamp":1733463254,"startTime":"0","endTime":"0","summary":"财中社12月6日电和誉-B（02256）发布自愿性公告，宣布其附属公司上海和誉生物医药科技有限公司在2024年欧洲肿瘤内科学会亚洲年会（ESMOAsia2024）上以口头报告形式展示了其自主研发的口服PD-L1抑制剂ABSK043治疗晚期实体瘤患者的最新一期研究结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412063261374835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2489427662","title":"和誉(02256)：已于欧洲肿瘤内科学会亚洲年会展示口服PD-L1抑制剂ABSK043的最新1期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489427662","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489427662?lang=zh_cn&edition=full","pubTime":"2024-12-06 12:26","pubTimestamp":1733459170,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和誉(02256)公告，公司之附属公司上海和誉生物医药科技有限公司（“和誉医药”）宣布，其已在于新加坡举办的2024年欧洲肿瘤内科学会亚洲年会（“ESMO Asia 2024”）上以口头报告形式展示其自主研发的口服PD-L1抑制剂ABSK043治疗晚期实体瘤患者的最新1期研究结果。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949131","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4023","BK1161","02256","LU1169590202.USD","LU2488822045.USD","PD"],"gpt_icon":0},{"id":"2489876422","title":"和誉-B(02256)：和誉医药以口头报告形式展示其口服PD-L1抑制剂 ABSK043的最新1期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489876422","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489876422?lang=zh_cn&edition=full","pubTime":"2024-12-06 12:04","pubTimestamp":1733457895,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，该公司的附属公司上海和誉生物医药科技有限公司宣布，其已在于新加坡举办的2024年欧洲肿瘤内科学会亚洲年会上以口头报告形式展示其自主研发的口服PD-L1 抑制剂ABSK043治疗晚期实体瘤患者的最新1期研究结果。研究结果表明，在600mg-1000mg BID剂量组，ABSK043单药具有良好的安全性和抗肿瘤活性。这些发现将持续支持ABSK043在EGFR突变肺癌和各种其他实体瘤中的进一步研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","BK1574","LU1169590202.USD","PD","BK1515","159938","LU2488822045.USD","LU1169589451.USD","02256","09939","BK1161"],"gpt_icon":0},{"id":"2489177366","title":"和誉-B(02256)下跌5.35%，报4.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489177366","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489177366?lang=zh_cn&edition=full","pubTime":"2024-12-05 10:23","pubTimestamp":1733365389,"startTime":"0","endTime":"0","summary":"12月5日，和誉-B(02256)盘中下跌5.35%，截至10:23，报4.6元/股，成交1707.55万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/05102346039645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2489103679","title":"和誉-B盘中异动 急速下挫5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489103679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489103679?lang=zh_cn&edition=full","pubTime":"2024-12-05 10:23","pubTimestamp":1733365381,"startTime":"0","endTime":"0","summary":"2024年12月05日早盘10时23分，和誉-B股票出现异动，股价快速下挫5.35%。截至发稿，该股报4.600港元/股，成交量377.2万股，换手率0.56%，振幅6.79%。和誉-B股票所在的生物技术行业中，整体跌幅为1.22%。和誉-B公司简介：和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205102301a1d51a63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205102301a1d51a63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2488968203","title":"港股异动 | 和誉-B(02256)涨超3% 附属治疗实体瘤抑制剂获美国批准临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2488968203","media":"智通财经","labels":["executive","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488968203?lang=zh_cn&edition=full","pubTime":"2024-12-03 14:45","pubTimestamp":1733208332,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B(02256)涨超3%，截至发稿，涨3.16%，报4.9港元，成交额1898万港元。消息面上，和誉公告，12月3日，上海和誉生物医药科技有限公司今天宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131获得FDA的IND批准。此次获批的是在晚期实体瘤患者中开展I期临床试验，试验题为“一项评估ABSK131在晚期╱转移性实体瘤患者中的安全性、耐受性、药代动力学和初步有效性的1期、首次人体、多中心、开放性研究”。研究人群主要为抑癌基因MTAP缺失的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","LU2488822045.USD","BK1576","02256","BK1583","03347","BK1161"],"gpt_icon":0},{"id":"2488952976","title":"和誉附属公司获FDA批准开展ABSK131临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2488952976","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488952976?lang=zh_cn&edition=full","pubTime":"2024-12-03 14:09","pubTimestamp":1733206172,"startTime":"0","endTime":"0","summary":"财中社12月3日电和誉-B（02256）发布公告称，其附属公司上海和誉生物医药科技有限公司（公司）于2024年12月3日宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131获得美国FDA的IND批准。这一批准将用于在晚期实体瘤患者中开展I期临床试验，主要研究抑癌基因MTAP缺失患者的安全性、耐受性、药代动力学及初步有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412033257675829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1141","LU2488822045.USD","03347","BK1576","02256","BK1161"],"gpt_icon":0},{"id":"2488959727","title":"和誉-B：创新PRMT5*MTA抑制剂ABSK131获得美国FDA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2488959727","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488959727?lang=zh_cn&edition=full","pubTime":"2024-12-03 12:48","pubTimestamp":1733201280,"startTime":"0","endTime":"0","summary":"　　和誉-B发布公告，2024年12月3日，上海和誉生物医药科技有限公司今天宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131获得FDA的 IND批准。此次获批的是在晚期实体瘤患者中开展I期临床试验，试验题为“一项评估ABSK131在晚期╱转移性实体瘤患者中的安全性、耐受性、药代动力学和初步有效性的1期、首次人体、多中心、开放性研究”。研究人群主要为抑癌基因MTAP缺失的患者。其中，间皮瘤及胰腺癌尚无已获批靶向治疗药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-03/doc-incyeerr1724695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","02256","MTA","BK1161","BK4188"],"gpt_icon":0},{"id":"2488968981","title":"和誉(02256)：高选择性小分子PRMT5*MTA抑制剂ABSK131获得FDA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2488968981","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488968981?lang=zh_cn&edition=full","pubTime":"2024-12-03 12:21","pubTimestamp":1733199689,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和誉(02256)公告，公司之附属公司上海和誉生物医药宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131获得FDA的IND批准。","market":"us","thumbnail":"https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948843","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4188","BK1161","LU2488822045.USD","02256","MTA"],"gpt_icon":0},{"id":"2488953699","title":"和誉(02256.HK)附属治疗实体瘤抑制剂获美国批准临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2488953699","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488953699?lang=zh_cn&edition=full","pubTime":"2024-12-03 12:16","pubTimestamp":1733199360,"startTime":"0","endTime":"0","summary":"和誉-B(02256.HK) 公布，其附属和誉医药的高选择性小分子PRMT5*MTA抑制剂ABSK131获得美国食品药管局(FDA)的新药临床试验(IND)批准。此次获批的是在晚期实体瘤患者中开展I期临床试验，试验题为“一项评估ABSK131在晚期/转移性实体瘤患者中的安全性、耐受性、药代动力学和初步有效性的1期、首次人体、多中心、开放性研究”。研究人群主要为抑癌基因MTAP缺失的患者。(jl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211028115122107_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211028115122107_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401385/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03347","BK1583","LU2488822045.USD","BK1576","02256","BK1141","BK1161"],"gpt_icon":0},{"id":"2488195846","title":"和誉-B(02256)：创新PRMT5*MTA抑制剂ABSK131 IND申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2488195846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488195846?lang=zh_cn&edition=full","pubTime":"2024-12-03 12:10","pubTimestamp":1733199048,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，2024年12月3日，上海和誉生物医药科技有限公司今天宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131获得FDA的 IND批准。约15%的人类实体肿瘤缺乏抑癌基因MTAP的表达。其中，间皮瘤及胰腺癌尚无已获批靶向治疗药物。MTAP缺失会导致其底物甲硫代腺苷积累，进而抑制PRMT5的活性。PRMT5与MTAP缺失表现出“合成致死”效应。近期研究表明，选择性靶向抑制PRMT5*MTA有望成为MTAP 缺失型癌症的治疗策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02256","BK4188","BK1161","MTA"],"gpt_icon":0},{"id":"2488610107","title":"和誉-B盘中异动 早盘股价大涨5.83%报4.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488610107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488610107?lang=zh_cn&edition=full","pubTime":"2024-12-02 11:16","pubTimestamp":1733109402,"startTime":"0","endTime":"0","summary":"2024年12月02日早盘11时16分，和誉-B股票出现异动，股价大幅拉升5.83%。截至发稿，该股报4.900港元/股，成交量151.6万股，换手率0.22%，振幅7.13%。资金方面，该股资金流入350.557万港元，流出23.087万港元。和誉-B股票所在的生物技术行业中，整体涨幅为0.37%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202111642971b18c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202111642971b18c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2487300152","title":"和誉-B(02256)上涨5.0%，报4.62元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2487300152","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487300152?lang=zh_cn&edition=full","pubTime":"2024-11-29 14:11","pubTimestamp":1732860674,"startTime":"0","endTime":"0","summary":"11月29日，和誉-B(02256)盘中上涨5.0%，截至14:11，报4.62元/股，成交734.19万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/29141145832927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2487589300","title":"和誉-B盘中异动 急速拉升5.00%报4.620港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2487589300","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487589300?lang=zh_cn&edition=full","pubTime":"2024-11-29 14:10","pubTimestamp":1732860658,"startTime":"0","endTime":"0","summary":"2024年11月29日下午盘14时10分，和誉-B股票出现波动，股价大幅上涨5.00%。截至发稿，该股报4.620港元/股，成交量156.7万股，换手率0.23%，振幅4.55%。资金方面，该股资金流入274.093万港元，流出347.701万港元。和誉-B股票所在的生物技术行业中，整体涨幅为1.64%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112914105898e454f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112914105898e454f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2486720105","title":"港股异动 | 和誉-B(02256)涨超5% 附属完成ABSK061-201首例胃癌患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2486720105","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486720105?lang=zh_cn&edition=full","pubTime":"2024-11-25 14:24","pubTimestamp":1732515851,"startTime":"0","endTime":"0","summary":"消息面上，和誉发布公告称，公司的附属公司上海和誉生物医药科技有限公司宣布，已完成“一项评估ABSK061和ABSK043联合或不联合化疗在FGFR2/3改变的转移性/不可切除的实体瘤患者中的安全性及有效性的开放性多中心II期临床研究”的首例胃癌患者给药。ABSK043是一种靶向PD-L1的口服小分子抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2486472667","title":"投资者速看！“第九届智通财经资本市场年会”活动报名中！","url":"https://stock-news.laohu8.com/highlight/detail?id=2486472667","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486472667?lang=zh_cn&edition=full","pubTime":"2024-11-25 10:32","pubTimestamp":1732501959,"startTime":"0","endTime":"0","summary":"“立根中国资产·破岩2025”第九届智通财经资本市场年会，将于2024年12月11-13日在深圳、香港两地隆重举行！盛会设置四大专题版块：“第九届智通财经资本市场年会暨上市公司颁奖典礼”、“智通财经新春策略会”、第二届中资海外基金高峰论坛暨新智奖颁奖典礼、金中环论坛（香港）。作为大会主旋律之一的 “智通财经新春策略会”将在12月11日下午至12日（全天）举行，届时将有100+港、美、A股上市公司集中正向路演。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","00857","01600","01313","06633","03877","00666","01558","09616","09959","02598","03700","09877","01651","02190","01450","01907","02411","02171","01755","02858","03306","03800","00826","02268","02362","02498","06821","06608","06830","06919","00086","00363","02273","01083","02256","00992","01783","02420","09919","06609","03709","01672","06098","00552","00302","00861","02105","00855","09911"],"gpt_icon":0},{"id":"2486355744","title":"和誉-B(02256)上涨5.26%，报4.4元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486355744","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486355744?lang=zh_cn&edition=full","pubTime":"2024-11-25 09:41","pubTimestamp":1732498897,"startTime":"0","endTime":"0","summary":"11月25日，和誉-B(02256)盘中上涨5.26%，截至09:41，报4.4元/股，成交126.74万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/25094145626820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2486983744","title":"和誉-B盘中异动 早盘大幅拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486983744","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486983744?lang=zh_cn&edition=full","pubTime":"2024-11-25 09:41","pubTimestamp":1732498875,"startTime":"0","endTime":"0","summary":"2024年11月25日早盘09时41分，和誉-B股票出现异动，股价大幅上涨5.02%。截至发稿，该股报4.390港元/股，成交量22.4万股，换手率0.03%，振幅3.59%。和誉-B股票所在的生物技术行业中，整体涨幅为0.19%。和誉-B公司简介：和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125094116abdc8312&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125094116abdc8312&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2485288285","title":"和誉完成II期临床研究首例胃癌患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485288285","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485288285?lang=zh_cn&edition=full","pubTime":"2024-11-22 13:46","pubTimestamp":1732254380,"startTime":"0","endTime":"0","summary":"财中社11月22日电和誉-B（02256）发布自愿性公告，宣布其附属公司上海和誉生物医药科技有限公司已完成一项II期临床研究的首例胃癌患者给药。该研究旨在评估口服PD-L1小分子抑制剂ABSK043与FGFR2/3小分子抑制剂ABSK061联合或不联合化疗在FGFR2/3改变的转移性或不可切除的实质瘤患者中的安全性及有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411223247943127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2485340411","title":"和誉-B(02256)：口服PD-L1小分子抑制剂ABSK043联合FGFR2/3小分子抑制剂ABSK061治疗实体瘤的II期临床完成首例胃癌患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485340411","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485340411?lang=zh_cn&edition=full","pubTime":"2024-11-22 12:25","pubTimestamp":1732249557,"startTime":"0","endTime":"0","summary":"剂量递增将评估ABSK061及ABSK043在FGFR2/3激活改变或过表达的转移性/不可切除的晚期实体瘤患者中的安全性、耐受性、初步疗效和PK特征，并推荐用于扩展期的给药剂量。ABSK043为一款全新的具备优异活性及高度选择性的口服小分子PD-L1抑制剂。截至目前，全球已有多款PD-1/PD-L1单抗药物获批上市，但并无PD-1/PD-L1口服小分子药物获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","LU2488822045.USD","BK4023","BK1161","LU1169589451.USD","02256","LU1169590202.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":0.0497},{"period":"1month","weight":0.1599},{"period":"3month","weight":0.5331},{"period":"6month","weight":0.6364},{"period":"1year","weight":0.369},{"period":"ytd","weight":0.3315}],"compareEarnings":[{"period":"1week","weight":0.0228},{"period":"1month","weight":-0.0327},{"period":"3month","weight":0.1388},{"period":"6month","weight":0.0816},{"period":"1year","weight":0.2153},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司致力于发现及开发创新且差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK011是一种有效的高选择性小分子成纤维细胞生长因子受体4（FGFR4）抑制剂。ABSK091是一种分子靶向候选产品，是FGFR亚型1、2及3的高效及选择性抑制剂。该公司的产品主要用于治疗肝细胞癌（HCC）、尿路上皮癌（UC）及胃癌（GC）。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.206623},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.021578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.062878},{"month":4,"riseRate":0.333333,"avgChangeRate":0.018452},{"month":5,"riseRate":0,"avgChangeRate":-0.043841},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.013147},{"month":7,"riseRate":0.666667,"avgChangeRate":0.049332},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.050943},{"month":9,"riseRate":0.666667,"avgChangeRate":0.042883},{"month":10,"riseRate":0.666667,"avgChangeRate":0.004984},{"month":11,"riseRate":0.75,"avgChangeRate":0.204437},{"month":12,"riseRate":0.25,"avgChangeRate":-0.079276}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}